Live Markets »News & Advice»Market News»Market News Details
Market News Details
Back

Dr Reddy's Laboratories acquires a portfolio of 42 ANDAs in US

Press Trust of India/New Delhi 13 Apr 19 | 09:15 PM

Drug major Dr Reddy's Laboratories Saturday said it has acquired a portfolio of 42 abbreviated new drug applications (ANDAs) in the US.

The company said it has entered into a definitive agreement to acquire yet to be marketed portfolio of ANDAs, including more than 30 generic injectable products, Dr Reddy's Laboratories said in a regulatory filing.

Related Stories

    No Related Stories Found
Widgets Magazine

These products will require to be technology transferred and could be launched within the next one to two years, it added.

ALSO READ: Dr Reddy's Q3 net profit up 45% at Rs 485 crore on lower tax outgo

The value of total addressable market for these products in the US is around $ 645 million for the calendar year ending in December 2018.

"The acquisition is in line with our stated strategy to significantly enhance our portfolio in our chosen growth markets," Dr Reddy's Laboratories CEO Erez Israeli said.

This transaction will help augment company's injectables product portfolio in the US market and globally, he added.

Widgets Magazine

Sensex

Company Price Gain (%)
Yes Bank114.5510.94
Sun Pharma.Inds.390.604.01
IndusInd Bank1,435.503.80
Larsen & Toubro1,556.153.36
ICICI Bank433.353.20

Poll

Currently No Poll Available.

Online Portfolio

You can create Online Portfolio here using the below button.

Widgets Magazine